One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
What Can Longitudinal Observational Studies of Physical Activity Teach Us About Prevention of Dementia?
Nicole L. Spartano, View ORCID ProfileLeonardo Pantoni
doi : 10.1212/WNL.0000000000011376
February 16, 2021; 96 (7)
Alzheimer Disease Spectrum Syndrome and Etiology From Clinical and PET Imaging Perspectives
David S. Knopman, William J. Jagust
doi : 10.1212/WNL.0000000000011415
February 16, 2021; 96 (7)
Mesenchymal Stem Cells for Ischemic Stroke
Leonardo Roever, Glen C. Jickling
doi : 10.1212/WNL.0000000000011491
February 16, 2021; 96 (7)
Prospective Analysis of Leisure-Time Physical Activity in Midlife and Beyond and Brain Damage on MRI in Older Adults
Priya Palta, A. Richey Sharrett, View ORCID ProfileKelley Pettee Gabriel, Rebecca F. Gottesman, Aaron R. Folsom, Melinda C. Power, Kelly R. Evenson, Clifford R. Jack, David S. Knopman, Thomas H. Mosley, Gerardo Heis
doi : 10.1212/WNL.0000000000011375
February 16, 2021; 96 (7)
Objective To test the hypothesis that greater levels of leisure-time moderate to vigorous intensity physical activity (MVPA) in midlife or late life are associated with larger gray matter volumes, less white matter disease, and fewer cerebrovascular lesions measured in late life, we utilized data from 1,604 participants enrolled in the Atherosclerosis Risk in Communities study.
Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE ?4, and Cognitive Impairment
oseph Therriault, Tharick A. Pascoal, Andrea L. Benedet, Cecile Tissot, Melissa Savard, Mira Chamoun, Firoza Lussier, Min Su Kang, Gleb Berzgin, Tina Wang, Jaime Fernandes-Arias, Gassan Massarweh, Jean-Paul Soucy, View ORCID ProfilePaolo Vitali, Paramita Saha-Chaudhuri, Serge Gauthier, View ORCID ProfilePedro Rosa-Neto
doi : 10.1212/WNL.0000000000011416
February 16, 2021; 96 (7)
Objective To assess the frequency of biologically defined Alzheimer disease (AD) in relation to age, sex, APOE ?4, and clinical diagnosis in a prospective cohort study evaluated with amyloid-PET and tau-PET.
CT-Visible Convexity Subarachnoid Hemorrhage is Associated With Cortical Superficial Siderosis and Predicts Recurrent ICH
Qi Li, Maria Clara Zanon Zotin, Andrew D. Warren, Yuan Ma, Edip Gurol, Joshua N. Goldstein, Steven M. Greenberg, Andreas Charidimou, View ORCID ProfileNicolas Raposo, Anand Viswanathan
doi : 10.1212/WNL.0000000000011052
February 16, 2021; 96 (7)
Objective To investigate whether acute convexity subarachnoid hemorrhage (cSAH) detected on CT in lobar intracerebral hemorrhage (ICH) related to cerebral amyloid angiopathy (CAA) is associated with recurrent ICH.
Long-Term Vascular Outcomes in Patients With Mixed Location Intracerebral Hemorrhage and Microbleeds
Hsin-Hsi Tsai, Szu-Ju Chen, Li-Kai Tsai, View ORCID ProfileMarco Pasi, Yen-Ling Lo, Ya-Fang Chen, Sung-Chun Tang, Jiann-Shing Jeng
doi : 10.1212/WNL.0000000000011378
February 16, 2021; 96 (7)
Objective To determine whether mixed location intracerebral hemorrhages/microbleeds (mixed ICH) is a risk factor for vascular unfavorable outcome compared to cerebral amyloid angiopathy–related ICH (CAA-ICH) or strictly deep hypertensive ICH/microbleeds (HTN-ICH).
Prevalence of Cervical Artery Dissection Among Hospitalized Patients With Stroke by Age in a Nationally Representative Sample From the United States
Yahya B. Atalay, Pirouz Piran, Abhinaba Chatterjee, Santosh Murthy, Babak B. Navi, Ava L. Liberman, Joseph Dardick, Cenai Zhang, Hooman Kamel, Alexander E. Merkler
doi : 10.1212/WNL.0000000000011420
February 16, 2021; 96 (7)
Objective To test the hypothesis that the prevalence of cervical artery dissection remains constant across age groups, we evaluated the relationship between age and cervical artery dissection in patients with stroke using a nationally representative sample from the United States.
Efficacy and Safety of Intravenous Mesenchymal Stem Cells for Ischemic Stroke
Jong-Won Chung, Won Hyuk Chang, Oh Young Bang, View ORCID ProfileGyeong Joon Moon, Suk Jae Kim, Soo-Kyoung Kim, Jin Soo Lee, View ORCID ProfileSung-Il Sohn, Yun-Hee Kim, for the STARTING-2 Collaborators
doi : 10.1212/WNL.0000000000011440
February 16, 2021; 96 (7)
Objective To test whether autologous modified mesenchymal stem cells (MSCs) improve recovery in patients with chronic major stroke.
The STARS Phase 2 Study
Lynne M. Bird, Cesar Ochoa-Lubinoff, Wen-Hann Tan, Gali Heimer, Raun D. Melmed, Amit Rakhit, Jeannie Visootsak, Matthew J. During, Christina Holcroft, Rebecca D. Burdine, Alexander Kolevzon, Ronald L. Thibert
doi : 10.1212/WNL.0000000000011409
February 16, 2021; 96 (7)
Objective To evaluate safety and tolerability and exploratory efficacy end points for gaboxadol (OV101) compared with placebo in individuals with Angelman syndrome (AS).
Association of GBA Genotype With Motor and Functional Decline in Patients With Newly Diagnosed Parkinson Disease
View ORCID ProfileJodi Maple-Gr?dem, View ORCID ProfileIngvild Dalen, View ORCID ProfileOle-Bj?rn Tysnes, View ORCID ProfileAngus D. Macleod, View ORCID ProfileLars Forsgren, View ORCID ProfileCarl E. Counsell, View ORCID ProfileGuido Alves
doi : 10.1212/WNL.0000000000011411
February 16, 2021; 96 (7)
Objective To establish the significance of glucocerebrosidase gene (GBA) carrier status on motor impairment in a large cohort of patients with incident Parkinson disease (PD).
Population-Based Prevalence of Myotonic Dystrophy Type 1 Using Genetic Analysis of Statewide Blood Screening Program
Nicholas E. Johnson, View ORCID ProfileRussell J. Butterfield, Katie Mayne, Tara Newcomb, Carina Imburgia, Diane Dunn, Brett Duval, Marcia L. Feldkamp, Robert B. Weiss
doi : 10.1212/WNL.0000000000011425
February 16, 2021; 96 (7)
Objective To determine whether the genetic prevalence of the CTG expansion in the DMPK gene associated with myotonic dystrophy type 1 (DM1) in an unbiased cohort is higher than previously reported population estimates, ranging from 5 to 20 per 100,000 individuals.
CLIA Laboratory Testing for Facioscapulohumeral Dystrophy
Autumn Rieken, Aaron D. Bossler, Katherine D. Mathews, View ORCID ProfileSteven A. Moore
doi : 10.1212/WNL.0000000000011412
February 16, 2021; 96 (7)
Objective To summarize facioscapulohumeral muscular dystrophy (FSHD) diagnostic testing results from the University of Iowa Molecular Pathology Laboratory.
Risk of Venous Thromboembolism in Grade II–IV Gliomas as a Function of Molecular Subtype
Maria Diaz, View ORCID ProfileJasmin Jo, Mark Smolkin, View ORCID ProfileSarah Jane Ratcliffe, David Schiff
doi : 10.1212/WNL.0000000000011414
February 16, 2021; 96 (7)
no abstract
Spatiotemporal Patterns of High-Frequency Activity (80–170 Hz) in Long-Term Intracranial EEG
View ORCID ProfileZhuying Chen, View ORCID ProfileDavid B. Grayden, View ORCID ProfileAnthony N. Burkitt, Udaya Seneviratne, View ORCID ProfileWendyl J. D'Souza, Chris French, Philippa J. Karoly, Katrina Dell, Kent Leyde, Mark J. Cook, View ORCID ProfileMatias I. Maturana
doi : 10.1212/WNL.0000000000011408
February 16, 2021; 96 (7)
Objective To determine the utility of high-frequency activity (HFA) and epileptiform spikes as biomarkers for epilepsy, we examined the variability in their rates and locations using long-term ambulatory intracranial EEG (iEEG) recordings.
Absence of GluD2 Antibodies in Patients With Opsoclonus-Myoclonus Syndrome
View ORCID ProfileMar Petit-Pedrol, View ORCID ProfileMar Guasp, View ORCID ProfileThais Armangue, View ORCID ProfileCinzia Lavarino, View ORCID ProfileAndres Morales La Madrid, Albert Saiz, View ORCID ProfileFrancesc Graus, View ORCID ProfileJosep Dalmau
doi : 10.1212/WNL.0000000000011410
February 16, 2021; 96 (7)
Objective A recent study showed glutamate receptor delta 2 antibodies (GluD2-ab) in sera of patients with opsoclonus-myoclonus syndrome (OMS). Inconsistencies between cerebellar immunoreactivity and expression of GluD2 led us to hypothesize that these antibodies are not biomarkers of OMS.
What's Happening in Neurology® Genetics
doi : 10.1212/WNL.0000000000011423
February 16, 2021; 96 (7)
What Is the Mechanism of Therapeutic and Adverse Effects of Gabapentinoids?
Eduardo E. Benarroch
doi : 10.1212/WNL.0000000000011424
February 16, 2021; 96 (7)
Henry R. Viets, MD, and the History of Myasthenia Gravis
Robert M. Feibel
doi : 10.1212/WNL.0000000000011239
February 16, 2021; 96 (7)
Henry R. Viets (1890–1969) was both a noted neurologist and medical historian. While at Harvard Medical School, from which he graduated in 1916, he attracted the attention of Harvey Cushing who directed Viets into these disciplines. Cushing arranged for Viets to take a fellowship in Oxford in the year after his graduation. With Cushing's recommendation, he lived with Sir William and Lady Osler and did research with the famous neurologist Sir Charles Sherrington. Viets was in London in 1935 when he heard about the remarkable success of Mary Walker in treating myasthenia gravis, first with physostigmine and then with neostigmine (Prostigmin). Securing an ampoule of this drug, he took it to the Massachusetts General Hospital where he was an attending neurologist and in March 1935 injected it into a myasthenic patient with great success. He established the first Myasthenia Gravis clinic in the world and was a pioneer in the treatment of this once obscure disease; he evaluated hundreds of patients and published many articles on myasthenia. He continued this association for more than 30 years. Under the tutelage of Cushing and Osler, Viets became a medical historian and bibliophile, publishing hundreds of articles and several books on many different subjects in the history of medicine. He was a president of the American Association for the History of Medicine and curator of the Boston Medical Library that eventually joined with the Harvard Medical School Library. Viets served on the Editorial Board of the New England Journal of Medicine for 40 years.
7T Epilepsy Task Force Consensus Recommendations on the Use of 7T MRI in Clinical Practice
Giske Opheim, View ORCID ProfileAnja van der Kolk, View ORCID ProfileKarin Markenroth Bloch, View ORCID ProfileAlbert J. Colon, Kathryn A. Davis, Thomas R. Henry, View ORCID ProfileJacobus F.A. Jansen, Stephen E. Jones, Jullie W. Pan, Karl R?ssler, View ORCID ProfileJoel M. Stein, Maria C. Strandberg, View ORCID ProfileSiegfried Trattnig, View ORCID ProfilePierre-Francois Van de Moortele, View ORCID ProfileMaria Isabel Vargas, Irene Wang, Fabrice Bartolomei, Neda Bernasconi, Andrea Bernasconi, Boris Bernhardt, View ORCID ProfileIsabella Bj?rkman-Burtscher, View ORCID ProfileMirco Cosottini, Sandhitsu R. Das, View ORCID ProfileLucie Hertz-Pannier, View ORCID ProfileSara Inati, View ORCID ProfileMichael T. Jurkiewicz, Ali R. Khan, Shuli Liang, View ORCID ProfileRuoyun Emily Ma, Srinivasan Mukundan, View ORCID ProfileHeath Pardoe, Lars H. Pinborg, View ORCID ProfileJonathan R. Polimeni, Jean-Philippe Ranjeva, Esther Steijvers, Steven Stufflebeam, Tim J. Veersema, Alexandre Vignaud, Natalie Voets, Serge Vulliemoz, Christopher J. Wiggins, Rong Xue, Renzo Guerrini, View ORCID ProfileMaxime Guye
doi : 10.1212/WNL.0000000000011413
February 16, 2021; 96 (7)
Identifying a structural brain lesion on MRI has important implications in epilepsy and is the most important factor that correlates with seizure freedom after surgery in patients with drug-resistant focal onset epilepsy. However, at conventional magnetic field strengths (1.5 and 3T), only approximately 60%–85% of MRI examinations reveal such lesions. Over the last decade, studies have demonstrated the added value of 7T MRI in patients with and without known epileptogenic lesions from 1.5 and/or 3T. However, translation of 7T MRI to clinical practice is still challenging, particularly in centers new to 7T, and there is a need for practical recommendations on targeted use of 7T MRI in the clinical management of patients with epilepsy. The 7T Epilepsy Task Force—an international group representing 21 7T MRI centers with experience from scanning over 2,000 patients with epilepsy—would hereby like to share its experience with the neurology community regarding the appropriate clinical indications, patient selection and preparation, acquisition protocols and setup, technical challenges, and radiologic guidelines for 7T MRI in patients with epilepsy. This article mainly addresses structural imaging; in addition, it presents multiple nonstructural MRI techniques that benefit from 7T and hold promise as future directions in epilepsy. Answering to the increased availability of 7T MRI as an approved tool for diagnostic purposes, this article aims to provide guidance on clinical 7T MRI epilepsy management by giving recommendations on referral, suitable 7T MRI protocols, and image interpretation.
Carotid Artery Stenosis in a Young Asymptomatic PatientThe Value of Multimodal Cross-Sectional Imaging
Camila Franco-Mesa, Young Erben, Michelle Lin, Josephine F. Huang, Sukhwinder S. Sandhu, Jason L. Siegel, Aziza Nassar, James F. Meschia
doi : 10.1212/WNL.0000000000011417
February 16, 2021; 96 (7)
Clinical Reasoning: A 63-Year-Old Woman Presenting With Bilateral Leg Pain
Joshua Budhu, Kathryn Holroyd, Denis Balaban, Wai-Ying Wendy Yau, Christopher Doughty, Edison Miyawaki, Helmut Rennke, Anthony Amato
doi : 10.1212/WNL.0000000000011220
February 16, 2021; 96 (7)
Pearls & Oy-sters: Number, Weaker, and Dizzier Due to Transthyretin Amyloidosis After 2 Liver Transplants
Alexan I. Yerevanian, View ORCID ProfileFrancy Shu
doi : 10.1212/WNL.0000000000011289
February 16, 2021; 96 (7)
Teaching NeuroImages: The Motor Band Sign in Amyotrophic Lateral Sclerosis
Joshua Budhu, Joseph Rosenthal, Erika Williams, Tracey Milligan
doi : 10.1212/WNL.0000000000010848
February 16, 2021; 96 (7)
Teaching Video Neuroimages: Ictal Unilateral Eye Blinking in Temporal Lobe Seizures
Emilia Raimondo, Robin McKinney, Katherine Mason, View ORCID ProfileLuca Bartolini
doi : 10.1212/WNL.0000000000010844
February 16, 2021; 96 (7)
Editors' Note: Asymptomatic Optic Nerve Lesions: An Underestimated Cause of Silent Retinal Atrophy in MS
Aravind Ganesh
doi : 10.1212/WNL.0000000000011442
February 16, 2021; 96 (7)
Editor Response: Asymptomatic Optic Nerve Lesions: An Underestimated Cause of Silent Retinal Atrophy in MS
Steven Galetta
doi : 10.1212/WNL.0000000000011443
February 16, 2021; 96 (7)
Author Response: Asymptomatic Optic Nerve Lesions: An Underestimated Cause of Silent Retinal Atrophy in MS
Olivier Outteryck, Xavier Leclerc
doi : 10.1212/WNL.0000000000011444
February 16, 2021; 96 (7)
Editors' Note: Optical Coherence Tomography for Detection of Asymptomatic Optic Nerve Lesions in Clinically Isolated Syndrome
Aravind Ganesh, Steven Galetta
doi : 10.1212/WNL.0000000000011448
February 16, 2021; 96 (7)
Reader Response: Optical Coherence Tomography for Detection of Asymptomatic Optic Nerve Lesions in Clinically Isolated Syndrome
Khichar Shubhakaran
doi : 10.1212/WNL.0000000000011446
February 16, 2021; 96 (7)
Author Response: Optical Coherence Tomography for Detection of Asymptomatic Optic Nerve Lesions in Clinically Isolated Syndrome
Olivier Outteryck
doi : 10.1212/WNL.0000000000011445
February 16, 2021; 96 (7)
